PMID- 17085310
OWN - NLM
STAT- MEDLINE
DCOM- 20070123
LR  - 20141120
IS  - 1083-8791 (Print)
IS  - 1083-8791 (Linking)
VI  - 12
IP  - 11
DP  - 2006 Nov
TI  - Human leukocyte antigen DR15 is associated with reduced relapse rate and improved 
      survival after human leukocyte antigen-identical sibling hematopoietic stem cell 
      transplantation.
PG  - 1169-75
AB  - Human leukocyte antigen (HLA) DR15 is associated with autoimmune cytopenia in 
      patients with aplastic anemia, myelodysplastic syndrome, and paroxysmal nocturnal 
      hemoglobinuria. Presence of this antigen also predicts response to 
      immunosuppressive treatment. If DR15 expression on hematopoietic cells also 
      favors induction of immune responses in an allogeneic setting, a lower relapse 
      rate after hematopoietic stem cell transplantation (HSCT) might result through an 
      enhanced graft-versus-leukemia effect. We retrospectively analyzed outcome of 
      HLA-identical sibling HSCT in 192 consecutive patients with acute or chronic 
      leukemia or non-Hodgkin lymphoma. Patients carrying the DR15 antigen had a higher 
      estimated 5-year overall survival (76%) than did DR15-negative patients (55%; P = 
      .04). Improved survival for DR15 patients was due to a significant decrease in 
      death from relapse (5% for DR15(+) versus 24% for DR15(-); P = .02), whereas no 
      difference was seen for rates of transplant-related mortality (19% and 21%, 
      respectively; P = .76). Findings were confirmed by multivariate analyses. Our 
      results show an association of DR15 with a decreased risk of disease relapse and 
      improved survival after HSCT for leukemia or non-Hodgkin lymphoma. This adds to 
      the growing list of links between DR15 and immune reactions in hematopoiesis.
FAU - Stern, Martin
AU  - Stern M
AD  - Department of Hematology, University Hospital, Basel, Switzerland.
FAU - Passweg, Jakob
AU  - Passweg J
FAU - Tiercy, Jean-Marie
AU  - Tiercy JM
FAU - Genitsch, Alexander
AU  - Genitsch A
FAU - Meyer-Monard, Sandrine
AU  - Meyer-Monard S
FAU - Heim, Dominik
AU  - Heim D
FAU - Tichelli, Andre
AU  - Tichelli A
FAU - Gratwohl, Alois
AU  - Gratwohl A
FAU - Nissen-Druey, Catherine
AU  - Nissen-Druey C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DR Serological Subtypes)
RN  - 0 (HLA-DR15 antigen)
SB  - IM
CIN - Biol Blood Marrow Transplant. 2007 Mar;13(3):371. PMID: 17317592
CIN - Biol Blood Marrow Transplant. 2007 Apr;13(4):493-4. PMID: 17382256
MH  - Cohort Studies
MH  - Graft vs Host Disease/immunology/*prevention & control
MH  - Graft vs Leukemia Effect/immunology
MH  - HLA-DR Antigens/*immunology
MH  - HLA-DR Serological Subtypes
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Leukemia/therapy
MH  - Lymphoma, Non-Hodgkin/therapy
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
MH  - *Secondary Prevention
MH  - Siblings
MH  - Transplantation, Isogeneic/*immunology
EDAT- 2006/11/07 09:00
MHDA- 2007/01/24 09:00
CRDT- 2006/11/07 09:00
PHST- 2006/06/22 00:00 [received]
PHST- 2006/07/06 00:00 [accepted]
PHST- 2006/11/07 09:00 [pubmed]
PHST- 2007/01/24 09:00 [medline]
PHST- 2006/11/07 09:00 [entrez]
AID - S1083-8791(06)00486-1 [pii]
AID - 10.1016/j.bbmt.2006.07.001 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2006 Nov;12(11):1169-75. doi: 
      10.1016/j.bbmt.2006.07.001.